Genprex, Inc., a leading gene therapy company dedicated to revolutionizing cancer and diabetes treatments, has recently achieved a significant milestone by securing patents in the United States and Europe for their innovative gene therapy, Reqorsa, in conjunction with PD-L1 and PD-1 antibodies. The US Patent and Trademark Office has granted a Notice of Allowance covering the utilization of Reqorsa alongside PD-L1 antibodies like Tecentriq, while the European Patent Office has issued a similar allowance for the combination with PD-1 antibodies. These patents, effective until at least 2037, mark a crucial step in fortifying Genprex’s intellectual property portfolio and enhancing the scope of their oncology program, particularly in relation to immune checkpoint inhibitors relevant to the Acclaim-3 clinical trial.
In addition to the US and European patents, Genprex has also received patents in Korea for the application of Reqorsa in combination with PD-L1 antibodies, further solidifying its global intellectual property footprint. The company is actively pursuing additional patent approvals in key regions such as Europe, Canada, Brazil, China, and Israel, which would significantly impact their ongoing Acclaim-3 clinical trial. Notably, patents for the utilization of Reqorsa with PD-1 antibodies have been granted in multiple countries including the US, Japan, Mexico, Russia, Australia, Chile, China, Korea, and Singapore, underscoring the broad international recognition of Genprex’s groundbreaking approach.
PD-L1 and PD-1 antibodies represent a cutting-edge form of targeted immunotherapy, forming part of a class of checkpoint inhibitors that disrupt the function of PD-L1 and PD-1 immune checkpoint proteins found on cell surfaces. The Acclaim-3 clinical trial, a phase 1/2 study, leverages a combination of Reqorsa and Genentech’s Tecentriq as a maintenance therapy for patients with extensive stage small cell lung cancer (ES-SCLC) who are eligible for ongoing treatment post Tecentriq and chemotherapy. This trial has garnered Fast Track Designation from the US Food and Drug Administration (FDA) for its focus on this patient group, further supported by the FDA Orphan Drug Designation, signifying the critical need for innovative therapies in this challenging medical landscape.
Genprex, Inc. stands out as a pioneering gene therapy company dedicated to addressing unmet medical needs in cancer and diabetes treatment spheres. Through their advanced technologies, Genprex aims to deliver disease-fighting genes to offer novel therapeutic solutions to a wide range of cancer and diabetes patients who face limited treatment options. The recent achievements in patent approvals for Reqorsa in combination with PD-L1 and PD-1 antibodies not only underscore the company’s commitment to innovation but also position them as key players in the evolving landscape of precision medicine and gene therapy.
Key Takeaways:
– Genprex’s patents for Reqorsa gene therapy with PD-L1 and PD-1 antibodies highlight the company’s commitment to advancing cancer treatment through innovative approaches.
– The Acclaim-3 clinical trial, supported by these patents, showcases the potential of combining gene therapy with immune checkpoint inhibitors for enhanced treatment outcomes in ES-SCLC patients.
– Genprex’s focus on intellectual property protection and strategic global patent filings underscores their dedication to expanding the reach of their pioneering therapies.
– The FDA recognitions received by the Acclaim-3 trial further validate the importance of Genprex’s work in addressing critical medical needs in cancer care.
Tags: gene therapy, immunotherapy
Read more on pharmabiz.com